Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topics
- Shortages and supply disruptions (15)
- Safety monitoring and information (10)
- Manufacturing (7)
- Compliance and enforcement (6)
- Labelling and packaging (4)
- Import and export (3)
- Legislation (3)
- Scheduling (national classification system) (3)
- Committees and advisory bodies (2)
- Advertising (1)
- Clinical trials (1)
- Fees and payments (1)
- Medicinal cannabis hub (1)
- Weight loss products (1)
Collection content
109 result(s) found, displaying 101 to 109
-
BlogYou might see a good deal on an overseas website, however, these health products are not approved for supply in Australia and have not been assessed by the TGA for safety, quality or effectiveness. You are not only risking your health, but you may also be left out of pocket if your online purchase is stopped at the border.
-
Medicine shortage alertsInformation about the cyclophosphamide and ifosfamide injection shortages.
-
Medicine shortage alertsThe overall supply of methylphenidate modified-release products continues to improve and stabilise.
-
Medicine shortage alertsSerious Scarcity Substitution Instrument extended due to continued shortages of HRT patch products.
-
Medicine shortage alertsPharmaceutical companies Novo Nordisk and Eli Lilly are discontinuing some of their insulin products.
-
Medicine shortage alertsSupply constraints will apply to Creon 25,000 unit and 35,000 unit capsules until 30 June 2026.
-
Medicine shortage alertsWe have approved overseas-registered substitutes for Pegasys 135 micrograms/0.5 mL and 180 micrograms/0.5 mL pre-filled syringes.
-
Corporate reportsThese guidelines apply to company-sponsored post-marketing surveillance studies of drug safety and toxicity
-
Corporate reportsTGA approach to disclosure of commercially confidential information (CCI)